Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. covers the month of May 2022. The report, dated May 3, 2022, serves as a vehicle to disseminate a press release (Exhibit 99.1) to U.S. investors. The registrant is a foreign private issuer based in Marseille, France, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text provided does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing consists solely of the cover page and an exhibit index referencing a press release.
Material Changes
No material changes to financial position or operations are detailed in the provided text. The document does not offer a comparison to prior periods or disclose specific operational updates beyond the existence of the referenced press release.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, risk factors, or details on contingencies. The content is limited to the formal submission of a press release dated May 3, 2022, signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) referenced in the filing to obtain the specific news or data being reported.
- Verify the date of the press release (May 3, 2022) against current market conditions to assess the timeliness of the information.
- Check subsequent filings for any updates or clarifications regarding the announcement made in this press release.
- Confirm the company's latest financial position by consulting the most recent Form 20-F or quarterly reports, as this 6-K contains no financial tables.